Announced details
Treatment of pediatric patients with achondroplasia (2–14 years old); domestic Phase 3 clinical trial
The Company's clinical trial registration information is published on jRCT
A system for submitting and publishing information on clinical research and related activities, overseen by the Ministry of Health, Labour and Welfare
jRCT2061260037 / expiration date: Not disclosed
No impact on full-year earnings for the fiscal year ending March 2027
The company does not address Contract Value / Offering price.
jRCT (Japan Registry of Clinical Trials), Ministry of Health, Labour and Welfare
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol (RBM-007, anti-FGF2 aptamer) |
| Counterparty | Ministry of Health, Labour and Welfare / jRCT (Japan Registry of Clinical Trials) |
| Counterparty overview | A system for submitting and publishing information on clinical research and related activities, overseen by the Ministry of Health, Labour and Welfare |
| Relationship with the Company | The Company's clinical trial registration information is published on jRCT |
| Applicable area | Treatment of pediatric patients with achondroplasia (2–14 years old); domestic Phase 3 clinical trial |
| Registration number and expiry date | jRCT2061260037 / expiration date: Not disclosed |
| Impact on Business Performance | No impact on full-year earnings for the fiscal year ending March 2027 |
| Source | jRCT (Japan Registry of Clinical Trials), Ministry of Health, Labour and Welfare |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Information on the trial was published on jRCT, which is overseen by the Ministry of Health, Labour and Welfare.